Development of at least 3 mechanistically oriented clinical studies of different tolerising therapies.

Development of at least 3 mechanistically oriented clinical studies of different tolerising therapies In terms of deliverables development implies all stages up to but excluding first patient first visit Whether the studies can be initiated or indeed completed during this IMI will depend on several factors including validation of the specific technology with a GMP process and regulatory documentation availability of funding approval of a protocol by partners ethical approvals and a trial sponsor